Verastem, Inc.
(NASDAQ : VSTM)

( )
VSTM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.91%195.591.2%$518.97m
GILDGilead Sciences, Inc.
-1.10%72.780.9%$459.77m
BIIBBiogen Inc.
-0.76%328.411.3%$384.66m
CELGCelgene Corporation
-0.91%81.831.2%$339.18m
ILMNIllumina, Inc.
-2.57%313.413.5%$297.65m
REGNRegeneron Pharmaceuticals, Inc.
-1.72%377.552.6%$228.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.37%121.492.0%$215.08m
VRTXVertex Pharmaceuticals Incorporated
-2.02%177.651.9%$210.48m
SRPTSarepta Therapeutics, Inc.
0.64%131.3416.4%$171.12m
AAgilent Technologies, Inc.
-0.92%65.631.5%$157.48m
BMRNBioMarin Pharmaceutical Inc.
-0.06%99.454.4%$135.37m
LGNDLigand Pharmaceuticals Incorporated
-1.24%200.0723.3%$115.36m
VKTXViking Therapeutics, Inc.
-1.80%14.200.9%$112.03m
NKTRNektar Therapeutics
0.35%49.085.6%$109.05m
EXASExact Sciences Corporation
-2.16%65.7725.3%$103.02m

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.